Renal Impairment Studies In Early Development Services: Innovative Patient Pharmacology Models for Phase I-IIa Support

By Gerd Arold and Nils Piwon, PRA Health Sciences

PRA Early Development Services has established a group of experts dedicated to early phase patient studies. Our innovative Patient Pharmacology Services (PPS) features a unique scientific/medical and operational model that enables us to conduct studies in patients with renal impairment following the same processes and guidelines that we apply to traditional Phase I or Phase IIa trials. This approach has demonstrated proven advantages compared to the standard monitor-based site management model and results in the delivery of faster and better patient pharmacology data to our clients. Having more than 20 years of experience and over 50 studies performed in this special area, we know how to do the job and, even better, we will do it for you in the shortest possible timeframe. When you select PRA to conduct your renal impairment trial, you can expect short timelines, dedicated and experienced staff and the highest-quality data.